tafasitamab

First Approval of Second-Line Therapy for DLBCL Bookmark

Article from MedPage Today curated by Contributing Editor George Lundberg, MD, who notes: 

The FDA has granted accelerated approval to tafasitamab (brand name Monjuvi) as a second-line therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), based upon overall responses seen in a clinical trial. This is the first FDA approval of a second-line treatment for this condition. There are few, if any, other options.

.